Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXICET 5 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXICET 5 500.
PAPA-DEINE #4 vs ROXICET 5/500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Oxycodone is a full opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and producing analgesic and antipyretic effects.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
1-2 tablets (5-10 mg oxycodone / 325-650 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 12 tablets per day (60 mg oxycodone / 6000 mg acetaminophen) in 24 hours.
None Documented
None Documented
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
Oxycodone: 3-5 hours (immediate-release); Acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged (up to 12-15 hours).
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Oxycodone: primarily hepatic metabolism to noroxycodone, oxymorphone, and conjugates; renal elimination of metabolites (about 60-87% as unchanged and metabolites), fecal < 10%. Acetaminophen: renal elimination of conjugates (90-100%), <5% unchanged.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination